Aardvark Therapeutics: RBC cuts target price to $2.5 from $6
AARD•RBC cut its target price for Aardvark Therapeutics to $2.5 from $6.
Related News
SLB expects fourth-quarter revenue of about $10 billion, up 5%-7% sequentially
SLB•
Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial
JAZZ•
How can EU limit impact of China Shock 2.0?
SPY•
Bristol Myers Squibb’s Zola-Cel shows early efficacy in Phase 1 multiple sclerosis trial
BMY•
Bloom Energy tumbles to two-month low despite earnings beat
BE•